Alvesco available for asthma sufferers in britain now Altana AG offers announced that Alvesco.

Further launches will follow during the full year in Europe and around the world. A lot more than 300 million people worldwide have problems with asthma, thereof approx. 10 million individuals in the united kingdom. IMS data reveal that the UK may be the largest market in European countries for asthma medicine. The marketplace in mono-therapy inhaled corticosteroids represented a value of some EUR1 billion in 2003, which the UK accounted for about 30 %. Hans-Joachim Lohrisch, CEO and President of Altana Pharma.Pivotal Research of ISTODAX in Peripheral T-Cell Lymphoma and Advance Regulatory Strategies Advance A LOT MORE THAN 20 Phase III and Pivotal Clinical Trials and 16 Preclinical Programs Addressing More Than 25 Critical and Debilitating Illnesses Initiate Apremilast Phase III Studies in Moderate-To-Severe Psoriasis and Psoriatic Arthritis, and Phase II Research in Rheumatoid Arthritis Initiate Pomalidomide Phase III Studies in Multiple Myeloma and Myelofibrosis Complete Amrubicin Phase III Trial in Sufferers With Little Cell Lung Cancer Initiate DLC-001, A Phase II/III Research of REVLIMID in Sufferers With Diffuse Huge B-Cell Lymphoma Initiate Multiple Phase II Trials for PDA-001 Cellular Therapy Initiate Stage II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus Initiate Stage I Trial of TORKi CC-223 Related StoriesMD Anderson research reveals why chemotherapy drugs not effective for most pancreatic cancer patientsNew findings reveal association between colorectal cancer tumor and melanoma drug treatmentFDA grants accelerated approval for Tagrisso to take care of sufferers with advanced NSCLCCelgene Company announced non-GAAP net gain of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010.

Other entries from category "urology":

Random entries